Skip to main content
Figure 1 | BMC Cancer

Figure 1

From: Cyproheptadine, an antihistaminic drug, inhibits proliferation of hepatocellular carcinoma cells by blocking cell cycle progression through the activation of P38 MAP kinase

Figure 1

Cytotoxicity of cyproheptadine toward normal human hepatocytes (HH) and HCC cell lines HepG2 and Huh-7. Cells in 96-well plates were cultured for 24 h, starved in serum-free medium for 24 h, and then treated with various concentrations of cyproheptadine for 24 h. Viability was determined for the treated cells using Cell Counting Kit-8. Data are presented as mean ± SD (n = 6). Significant differences from the no-treatment control, determined by one-way ANOVA and Dunnett’s comparison test, are indicated by asterisks: *p < 0.05; ***p < 0.001.

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us